NZ598557A - Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics - Google Patents

Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics

Info

Publication number
NZ598557A
NZ598557A NZ598557A NZ59855710A NZ598557A NZ 598557 A NZ598557 A NZ 598557A NZ 598557 A NZ598557 A NZ 598557A NZ 59855710 A NZ59855710 A NZ 59855710A NZ 598557 A NZ598557 A NZ 598557A
Authority
NZ
New Zealand
Prior art keywords
aptamers
tissue factor
pathway inhibitor
factor pathway
bleeding disorder
Prior art date
Application number
NZ598557A
Other languages
English (en)
Inventor
Jeffrey C Kurz
Emily Waters
Kathleen Mcginness
Robert G Schaub
Ryan Genga
John L Diener
Jennifer Nelson
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of NZ598557A publication Critical patent/NZ598557A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
NZ598557A 2009-08-18 2010-08-17 Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics NZ598557A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23493909P 2009-08-18 2009-08-18
US35337410P 2010-06-10 2010-06-10
US36636210P 2010-07-21 2010-07-21
US36776610P 2010-07-26 2010-07-26
PCT/US2010/045797 WO2011022427A1 (en) 2009-08-18 2010-08-17 Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics

Publications (1)

Publication Number Publication Date
NZ598557A true NZ598557A (en) 2013-08-30

Family

ID=43607310

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ598557A NZ598557A (en) 2009-08-18 2010-08-17 Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics

Country Status (17)

Country Link
US (1) US8252913B2 (OSRAM)
EP (1) EP2467167B1 (OSRAM)
JP (1) JP2013502218A (OSRAM)
KR (1) KR20120061086A (OSRAM)
CN (1) CN102869385A (OSRAM)
AU (1) AU2010284329B2 (OSRAM)
BR (1) BR112012003806A2 (OSRAM)
CA (1) CA2770762A1 (OSRAM)
CO (1) CO6531414A2 (OSRAM)
ES (1) ES2655589T3 (OSRAM)
IL (1) IL218048A0 (OSRAM)
IN (1) IN2012DN01984A (OSRAM)
MX (1) MX2012002133A (OSRAM)
NZ (1) NZ598557A (OSRAM)
RU (1) RU2012110221A (OSRAM)
SG (1) SG178408A1 (OSRAM)
WO (1) WO2011022427A1 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070166741A1 (en) 1998-12-14 2007-07-19 Somalogic, Incorporated Multiplexed analyses of test samples
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
ES2458665T5 (es) 2008-12-22 2021-06-30 Novo Nordisk As Anticuerpos contra el inhibidor de la vía del factor tisular
AU2012214148A1 (en) * 2011-02-11 2013-08-29 Baxter Healthcare S.A. Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
CA2837503C (en) 2011-06-08 2018-01-02 Miedzynarodowy Instytut Biologii Molekularnej I Komorkowej Sequence-specific engineered ribonuclease h and the method for determining the sequence preference of dna-rna hybrid binding proteins
WO2013142153A2 (en) * 2012-03-22 2013-09-26 Baxter International Inc. Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
DE102012020496A1 (de) 2012-10-18 2014-04-24 Charité - Universitätsmedizin Berlin Biomarker zur Diagnostik und Behandlung von Neurofibromatose Typ 1
JP6502930B2 (ja) * 2013-06-21 2019-04-17 イミジン， インコーポレイテッド 血液解析
JP6584397B2 (ja) 2013-07-19 2019-10-02 ノヴォ ノルディスク アー／エス 凝血促進活性を誘発することができる組織因子経路インヒビターのｎ末端部分を認識する抗体
JP6630273B2 (ja) 2013-09-09 2020-01-15 ソマロジック・インコーポレーテッド 安定性が向上したｐｄｇｆ及びｖｅｇｆアプタマー並びにｐｄｇｆ及びｖｅｇｆ媒介性の疾患及び障害の治療におけるそれらの使用
WO2015154090A1 (en) * 2014-04-04 2015-10-08 Bloodworks Routine laboratory and point-of-care (poc) testing for hemostasis
SG10202100131WA (en) * 2015-06-23 2021-02-25 Childrens Hospital Philadelphia Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
WO2017062536A2 (en) * 2015-10-06 2017-04-13 Kieu Hoang A method of manfacturing prothrombin complex concentrate from fraction iii and non-prothrombin complex concentrate from fraction iv
CN108368509B (zh) * 2015-12-04 2022-03-22 全药工业株式会社 改善了血中滞留性的抗il－17适体
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体
CN115792231B (zh) * 2022-11-04 2023-07-25 中拓生物有限公司 一种基于凝血酶适配体调节的酶级联反应的DNase I生物传感器

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5981471A (en) 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
EP1039935A4 (en) 1997-02-28 2005-04-27 Univ Iowa Res Found USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
PT1009413E (pt) 1997-09-05 2007-05-31 Univ California Utilização de oligonucleótidos imumoestimulantes para a prevenção ou tratamento da asma.
WO2000028082A1 (fr) 1998-11-09 2000-05-18 Eiken Kagaku Kabushiki Kaisha Procede de synthese d'acide nucleique
US6514948B1 (en) 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
WO2003102212A2 (en) * 2002-05-31 2003-12-11 Regents Of The University Of Minnesota In vitro evaluation of nucleic acid ligands
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
EP1919499A2 (en) * 2005-07-29 2008-05-14 Universiteit van Maastricht Regulation of tissue factor activity by protein s and tissue factor pathway inhibitor

Also Published As

Publication number Publication date
WO2011022427A1 (en) 2011-02-24
US20110098345A1 (en) 2011-04-28
JP2013502218A (ja) 2013-01-24
AU2010284329A1 (en) 2012-03-29
CA2770762A1 (en) 2011-02-24
BR112012003806A2 (pt) 2016-11-16
EP2467167A4 (en) 2013-12-25
US8252913B2 (en) 2012-08-28
IN2012DN01984A (OSRAM) 2015-07-24
CN102869385A (zh) 2013-01-09
EP2467167B1 (en) 2017-08-16
MX2012002133A (es) 2013-02-15
RU2012110221A (ru) 2013-09-27
ES2655589T3 (es) 2018-02-20
CO6531414A2 (es) 2012-09-28
EP2467167A1 (en) 2012-06-27
AU2010284329B2 (en) 2015-04-16
KR20120061086A (ko) 2012-06-12
IL218048A0 (en) 2012-04-30
SG178408A1 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
NZ598557A (en) Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
NZ592867A (en) Compositions and methods for inhibiting expression of transthyretin
NZ607870A (en) Lactococcus crispr-cas sequences
NZ593618A (en) Gnaq targeted dsrna compositions and methods for inhibiting expression
IN2012DN00403A (OSRAM)
NZ599032A (en) Modulation of huntingtin expression
MX355408B (es) Inhibidores a base de oligonucleotidos que comprenden un motivo de acido nucleico bloqueado.
AR079972A1 (es) Plantas tolerantes a herbicidas inhibidores de las hppd
NZ602618A (en) Aptamers to beta-ngf and their use in treating beta-ngf mediated diseases and disorders
IN2014DN03463A (OSRAM)
NZ597078A (en) CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS
PH12014500348A1 (en) Genes and proteins for alkanoyl-coa synthesis
EA201290560A1 (ru) Растения, устойчивые к гербицидам - ингибиторам hppd
WO2011056005A3 (ko) 안티센스 가닥에 의한 오프-타겟 효과를 최소화한 신규한 ｓｉＲＮＡ 구조 및 그 용도
CO6241167A2 (es) Arn circular monocatenario y metodo para producirlo
EA201290572A1 (ru) Растения, устойчивые к гербицидам - ингибиторам hppd
MX2018013216A (es) Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6).
MX2016007980A (es) Acido nucleico que induce acido ribonucleico de interferencia modificado para prevenir una falla en alcanzar el objetivo, y uso del mismo.
WO2010115202A3 (en) Methods and compositions for the specific inhibition of kras by blunt ended double-stranded rna
MX337801B (es) Acidos nucleicos que se enlazan on mcp-1.
MX362061B (es) Ácidos nucleicos de enlace c5a nuevos.
ATE528008T1 (de) Rnai-modulation von aha und ihre therapeutische verwendung
EP4335502A3 (en) Modified u6 promoter system for tissue specific expression
WO2010028054A8 (en) Compositions and methods for inhibiting expression of mutant egfr gene
MX2013003698A (es) Agente preventivo o terapeutico contra la fibrosis.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 17 AUG 2017 BY COMPUTER PACKAGES INC

Effective date: 20140828

ASS Change of ownership

Owner name: BAXALTA INC, US

Effective date: 20160414

Owner name: BAXALTA GMBH, CH

Effective date: 20160414

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 AUG 2018 BY COMPUTER PACKAGES INC

Effective date: 20170801

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 AUG 2019 BY ANAQUA SERVICES

Effective date: 20180719

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 AUG 2020 BY ANAQUA SERVICES

Effective date: 20190722

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 AUG 2021 BY ANAQUA SERVICES

Effective date: 20200721

ASS Change of ownership

Owner name: TAKEDA PHARMACEUTICAL COMPANY, JP

Effective date: 20210621

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 AUG 2022 BY ANAQUA SERVICES

Effective date: 20210720

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 AUG 2023 BY ANAQUA SERVICES

Effective date: 20220721

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 AUG 2024 BY ANAQUA SERVICES

Effective date: 20230720

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 AUG 2025 BY ANAQUA SERVICES

Effective date: 20240723

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 AUG 2026 BY ANAQUA SERVICES

Effective date: 20250724